| 高逸凡,林 莹,孙 哲,郭新红,徐 勇.利伐沙班和达比加群酯在高龄非瓣膜性房颤患者中的有效性及安全性观察[J].现代生物医学进展英文版,2019,19(13):2486-2489. |
| 利伐沙班和达比加群酯在高龄非瓣膜性房颤患者中的有效性及安全性观察 |
| A Retrospective Study of the Efficacy and Safety of Rivaroxaban and Dabigatran in Elderly Patients with Non-valvular AF |
| Received:March 02, 2019 Revised:March 23, 2019 |
| DOI：10.13241/j.cnki.pmb.2019.13.019 |
| 中文关键词: 非瓣膜性房颤 老年 利伐沙班 达比加群酯 |
| 英文关键词: Non-valvular AF Elderly Rivaroxaban Dabigatran |
| 基金项目:军队重大科研项目子课题（AWS14R010） |
| Author Name | Affiliation | E-mail | | GAO Yi-fan | Department of Cardiology, The First Medical Center of PLA General Hospital, Beijing, 100853, China | gyfran0202@163.com | | LIN Ying | Department of Cardiology, The First Medical Center of PLA General Hospital, Beijing, 100853, China | | | SUN Zhe | Department of Cardiology, The First Medical Center of PLA General Hospital, Beijing, 100853, China | | | GUO Xin-hong | Department of Cardiology, The First Medical Center of PLA General Hospital, Beijing, 100853, China | | | XU Yong | Department of Cardiology, The First Medical Center of PLA General Hospital, Beijing, 100853, China | |
|
| Hits: 1097 |
| Download times: 817 |
| 中文摘要: |
| 摘要 目的：探讨利伐沙班及达比加群酯在高龄老年非瓣膜性AF患者中应用的有效性及安全性。方法：回顾性分析2016年9月至2018年3月于我院心血管内科住院治疗的高龄非瓣膜性房颤患者202例（利伐沙班组116例，达比加群酯组86例），平均随访9个月，比较两组患者基本临床资料、栓塞事件和临床相关出血事件。结果：利伐沙班组和达比加群酯组各有4例患者达到有效性终点，两组药物有效性无显著性差异（P >0.05）。其中，缺血性脑卒中是最常见的栓塞事件（4/8）。利伐沙班组共有15例患者发生出血事件，达比加群酯组共有10例患者发生出血事件，两组药物安全性亦无显著性差异（P >0.05）。胃肠道出血是最常见的出血事件（7/25）。结论：利伐沙班及达比加群酯在高龄老年非瓣膜性AF患者中应用的有效性及安全性均无明显差异。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the efficacy and safety of Rivaroxaban and Dabigatran in elderly patients with non-valvular AF. Methods: A retrospective analysis of 202 elderly patients (Rivaroxaban = 116, Dabigatran = 86) with non-valvular atrial fibrillation hospitalized in our department of Cardiology from September 2016 to March 2018 was performed. The average follow-up period was 9 months. Comparation of the basic clinical data, the efficacy end point and clinical relevant bleeding between the two groups were done. Results: The efficacy end point occurred in 4 patients in the Rivaroxaban group and the Dabigatran group respectively. There was no significant difference in efficacy between the two groups (P > 0.05). Ischemic stroke was the most common thromboembolic events (4/8). Clinical relevant bleeding occurred in 15 patients in the Rivaroxaban group and 10 in the Dabigatran group. There was no significant difference in safety between the two groups (P > 0.05). Gastrointestinal bleeding was the most common bleeding events (7/25). Conclusion: The efficacy and safety of Rivaroxaban and Dabigartran in elderly patients with non-valvular AF are similar. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
